304 related articles for article (PubMed ID: 30229442)
1. Tafenoquine: First Global Approval.
Frampton JE
Drugs; 2018 Sep; 78(14):1517-1523. PubMed ID: 30229442
[TBL] [Abstract][Full Text] [Related]
2. Tafenoquine: a promising new antimalarial agent.
Crockett M; Kain KC
Expert Opin Investig Drugs; 2007 May; 16(5):705-15. PubMed ID: 17461742
[TBL] [Abstract][Full Text] [Related]
3. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Baird JK
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30380095
[TBL] [Abstract][Full Text] [Related]
5. Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax.
Tan KR; Hwang J
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30137454
[No Abstract] [Full Text] [Related]
6. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
[TBL] [Abstract][Full Text] [Related]
7. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
8. Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence.
Val F; Costa FT; King L; Brito-Sousa JD; Bassat Q; Monteiro WM; Siqueira AM; Luzzatto L; Lacerda MV
Future Microbiol; 2019 Oct; 14():1261-1279. PubMed ID: 31596137
[TBL] [Abstract][Full Text] [Related]
9. Tafenoquine: the new kid on the block.
Chen V; Daily JP
Curr Opin Infect Dis; 2019 Oct; 32(5):407-412. PubMed ID: 31305490
[TBL] [Abstract][Full Text] [Related]
10. Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.
Ebstie YA; Abay SM; Tadesse WT; Ejigu DA
Drug Des Devel Ther; 2016; 10():2387-99. PubMed ID: 27528800
[TBL] [Abstract][Full Text] [Related]
11. Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.
Berman J; Brown T; Dow G; Toovey S
Malar J; 2018 Nov; 17(1):407. PubMed ID: 30400893
[TBL] [Abstract][Full Text] [Related]
12. Tafenoquine: A Step toward Malaria Elimination.
Lu KY; Derbyshire ER
Biochemistry; 2020 Mar; 59(8):911-920. PubMed ID: 32073254
[TBL] [Abstract][Full Text] [Related]
13. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
Anjum MU; Naveed AK; Mahmood SN; Naveed OK
Travel Med Infect Dis; 2020; 36():101576. PubMed ID: 32036012
[TBL] [Abstract][Full Text] [Related]
14. Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Edstein MD; Walsh DS; Eamsila C; Sasiprapha T; Nasveld PE; Kitchener S; Rieckmann KH
Med Trop (Mars); 2001; 61(1):56-8. PubMed ID: 11584657
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
Walsh DS; Eamsila C; Sasiprapha T; Sangkharomya S; Khaewsathien P; Supakalin P; Tang DB; Jarasrumgsichol P; Cherdchu C; Edstein MD; Rieckmann KH; Brewer TG
J Infect Dis; 2004 Oct; 190(8):1456-63. PubMed ID: 15378438
[TBL] [Abstract][Full Text] [Related]
16. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Vélez ID; Hien TT; Green JA; Martin A; Sharma H; Rousell VM; Breton JJ; Ernest TB; Rolfe K; Taylor M; Mohamed K; Jones SW; Chau NH; Hoa NT; Duparc S; Tan LK; Goyal N
Lancet Child Adolesc Health; 2022 Feb; 6(2):86-95. PubMed ID: 34871570
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
Thakkar N; Green JA; Koh GCKW; Duparc S; Tenero D; Goyal N
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201820
[TBL] [Abstract][Full Text] [Related]
18. Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.
Duparc S; Chalon S; Miller S; Richardson N; Toovey S
Malar J; 2020 Mar; 19(1):111. PubMed ID: 32169086
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
[TBL] [Abstract][Full Text] [Related]
20. Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
Srinivasan S; Roy D; Chavas TEJ; Vlaskin V; Ho DK; Pottenger A; LeGuyader CLM; Maktabi M; Strauch P; Jackson C; Flaherty SM; Lin H; Zhang J; Pybus B; Li Q; Huber HE; Burke PA; Wesche D; Rochford R; Stayton PS
J Control Release; 2021 Mar; 331():213-227. PubMed ID: 33378692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
